CATALOGO DEI PRODOTTI DELLA RICERCA

Bria, Emilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.039
EU - Europa 10.112
AS - Asia 8.200
SA - Sud America 1.078
Continente sconosciuto - Info sul continente non disponibili 271
AF - Africa 180
OC - Oceania 14
Totale 32.894
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.583
RU - Federazione Russa 3.671
SG - Singapore 3.155
CN - Cina 2.745
GB - Regno Unito 2.171
IT - Italia 1.032
BR - Brasile 804
VN - Vietnam 669
HK - Hong Kong 643
DE - Germania 622
FR - Francia 609
FI - Finlandia 535
IE - Irlanda 493
SE - Svezia 485
KR - Corea 268
CA - Canada 193
BD - Bangladesh 141
IN - India 139
NL - Olanda 114
UA - Ucraina 102
AR - Argentina 88
JP - Giappone 65
ID - Indonesia 58
EC - Ecuador 54
TR - Turchia 54
MX - Messico 53
PL - Polonia 48
ZA - Sudafrica 47
IQ - Iraq 44
ES - Italia 42
CO - Colombia 37
CR - Costa Rica 35
BE - Belgio 33
GT - Guatemala 31
CH - Svizzera 28
CL - Cile 27
VE - Venezuela 26
AT - Austria 25
HN - Honduras 25
MA - Marocco 24
PK - Pakistan 24
NG - Nigeria 22
PR - Porto Rico 20
SA - Arabia Saudita 20
JM - Giamaica 19
NI - Nicaragua 17
PH - Filippine 17
PY - Paraguay 17
SV - El Salvador 17
UZ - Uzbekistan 17
MY - Malesia 16
TT - Trinidad e Tobago 16
IR - Iran 15
EU - Europa 14
NP - Nepal 14
CZ - Repubblica Ceca 13
KE - Kenya 13
PE - Perù 13
TN - Tunisia 13
EG - Egitto 12
LT - Lituania 12
AZ - Azerbaigian 11
IL - Israele 11
TG - Togo 11
AE - Emirati Arabi Uniti 10
AU - Australia 10
TH - Thailandia 10
CW - ???statistics.table.value.countryCode.CW??? 9
AL - Albania 8
BJ - Benin 8
EE - Estonia 8
GP - Guadalupe 8
LV - Lettonia 8
AM - Armenia 7
DZ - Algeria 7
OM - Oman 7
PT - Portogallo 7
RS - Serbia 7
BO - Bolivia 6
DK - Danimarca 6
GR - Grecia 6
DO - Repubblica Dominicana 5
JO - Giordania 5
BB - Barbados 4
CI - Costa d'Avorio 4
KZ - Kazakistan 4
MK - Macedonia 4
NO - Norvegia 4
UY - Uruguay 4
BS - Bahamas 3
CM - Camerun 3
CY - Cipro 3
GA - Gabon 3
GE - Georgia 3
KG - Kirghizistan 3
LK - Sri Lanka 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
RO - Romania 3
SI - Slovenia 3
Totale 32.591
Salva come PNG Salva come JPEG
Città #
Southend 1.869
Singapore 1.576
San Jose 1.412
Ashburn 1.402
Moscow 1.134
Chandler 1.067
Woodbridge 956
Dallas 869
Hong Kong 636
Ann Arbor 599
Dublin 488
Beijing 478
Council Bluffs 453
The Dalles 438
Jacksonville 436
Houston 422
Verona 363
Jinan 247
Ho Chi Minh City 242
Lawrence 235
Princeton 234
New York 221
Los Angeles 196
Wilmington 191
Munich 186
Nanjing 185
Shenyang 155
Hanoi 154
Santa Clara 144
Helsinki 130
Hebei 117
Buffalo 107
Redondo Beach 106
Tianjin 106
Changsha 79
Ningbo 77
Milan 75
São Paulo 74
Haikou 69
Guangzhou 62
Zhengzhou 60
Nanchang 59
Hangzhou 57
Columbus 56
Tokyo 55
Sindelfingen 53
London 52
Jiaxing 49
Taizhou 47
Frankfurt am Main 46
Seoul 46
Montreal 42
Orem 42
Chicago 41
Rome 39
Turku 39
Seattle 38
Brooklyn 37
Taiyuan 37
Chennai 35
Atlanta 34
Denver 34
Brussels 33
San Francisco 33
Fuzhou 30
Rio de Janeiro 30
Boardman 29
Warsaw 28
Amsterdam 27
Norwalk 27
Lancaster 26
Lanzhou 26
Toronto 26
Johannesburg 25
Falls Church 24
Phoenix 24
Redwood City 24
Dearborn 23
Guatemala City 23
San José 23
Mexico City 22
Abuja 21
Haiphong 21
Mumbai 21
Quito 21
Bologna 20
Naples 20
Stockholm 20
Baghdad 19
North Bergen 19
Boston 18
Da Nang 18
Jakarta 18
Zurich 18
Nuremberg 17
Belo Horizonte 16
Charlotte 16
Hải Dương 16
Porto Alegre 16
Shanghai 16
Totale 19.842
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 333
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 297
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 256
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 256
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 254
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 249
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 237
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 236
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 231
Adenocarcinoma of the paraurethral glands: a case report 226
Le linee guida AIOM, ASCO e MASCC-ESMO sull'emesi da chemioterapia e radioterapia: considerazioni e approfondimenti. 223
Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis 222
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 220
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 220
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 217
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 215
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 215
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 213
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 211
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 209
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 208
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 207
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 201
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 201
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 200
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 200
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 199
The development of PARP as a successful target for cancer therapy 196
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 196
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 195
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 195
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 194
Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 189
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 189
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 188
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 187
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 187
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 186
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 185
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 185
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 184
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 183
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 180
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients 179
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 178
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 176
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 175
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 172
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 172
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 172
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies 172
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 171
Do immune checkpoint inhibitors need new studies methodology? 170
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 167
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 167
2-weekly docetaxel: issues for clinical practice. 166
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 165
Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers 164
Clinical meta-analyses of targeted therapies in adenocarcinoma. 163
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 161
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 159
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 159
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 158
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 157
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 156
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 154
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 153
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 152
Acute emesis: Moderately emetogenic chemotherapy. 152
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment 152
Clinical meta-analyses of targeted therapies in adenocarcinoma. 151
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 151
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 148
Molecular Typing of Lung Adenocarcinoma on Cytological Samples in the Next-Generation Sequencing Era 144
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 144
Physical activity and exercise in lung cancer care: will promises be fulfilled? 143
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 143
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 143
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 142
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 142
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories 142
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study 140
Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology 140
Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success 139
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 139
Adjuvant chemotherapy for bladder cancer: the chance for meta-aalyses comparison 139
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 139
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 138
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 138
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer 136
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status 136
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 136
Chemotherapy in metastatic renal cell carcinoma today? A systematic review. 135
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 135
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 134
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 133
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 133
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 133
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 131
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences 130
Totale 17.794
Salva come PNG Salva come JPEG
Categoria #
all - tutte 119.983
article - articoli 113.097
book - libri 557
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 6.329
Totale 239.966
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022997 0 0 0 157 43 30 27 98 66 41 136 399
2022/20233.084 268 265 316 577 268 745 32 189 285 19 86 34
2023/20241.530 77 112 113 153 219 224 40 191 32 69 229 71
2024/20254.404 232 264 172 791 134 156 160 214 743 321 325 892
2025/202612.655 953 696 913 1.970 3.079 756 1.201 669 1.042 716 281 379
2026/20272.540 146 395 554 1.445 0 0 0 0 0 0 0 0
Totale 32.894